Immunome Inc (IMNM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunome Inc (IMNM) has a cash flow conversion efficiency ratio of -0.076x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-47.95 Million) by net assets ($634.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Immunome Inc (IMNM) balance sheet quality index to measure how much of total assets are equity-financed.
Immunome Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Immunome Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Immunome Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Immunome Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunome Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Go Digit General Insurance Ltd
NSE:GODIGIT
|
0.188x |
|
Levi Strauss & Co Class A
NYSE:LEVI
|
0.124x |
|
PSK Inc
KQ:319660
|
-0.026x |
|
Customers Bancorp, Inc.
NYSE:CUBI
|
0.016x |
|
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
|
-0.071x |
|
Hugo Boss AG
XETRA:BOSS
|
0.076x |
|
Thule Group AB
ST:THULE
|
0.007x |
|
Artisan Partners Asset Management Inc
NYSE:APAM
|
0.354x |
Annual Cash Flow Conversion Efficiency for Immunome Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Immunome Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Immunome Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $634.34 Million | $-190.92 Million | -0.301x | +50.79% |
| 2024-12-31 | $181.16 Million | $-110.79 Million | -0.612x | -868.76% |
| 2023-12-31 | $119.88 Million | $-7.57 Million | -0.063x | +96.34% |
| 2022-12-31 | $16.65 Million | $-28.69 Million | -1.723x | -355.47% |
| 2021-12-31 | $48.19 Million | $-18.23 Million | -0.378x | -28.88% |
| 2020-12-31 | $41.34 Million | $-12.13 Million | -0.293x | -208.92% |
| 2019-12-31 | $-35.63 Million | $-9.60 Million | 0.269x | -8.30% |
| 2018-12-31 | $-25.20 Million | $-7.41 Million | 0.294x | -- |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more